All Stories

  1. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A
  2. High proportion of patients with bleeding of unknown cause in persons with a mild-to-moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB)
  3. Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years
  4. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura
  5. Acquired hemophilia A: Updated review of evidence and treatment guidance
  6. Safety and pharmacokinetics of anti‐ TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial
  7. NET untangled in TMA?
  8. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study
  9. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans
  10. A novel flow‐based assay reveals discrepancies in ADAMTS‐13 inhibitor assessment as compared with a conventional clinical static assay
  11. Prognostic factors, long-term survival, and outcome of cancer patients receiving chemotherapy in the intensive care unit
  12. Inherited and Acquired Thrombotic Thrombocytopenic Purpura (TTP) in Adults
  13. Immune-Mediated Disorders Causing Bleeding or Thrombosis in Lymphoproliferative Diseases
  14. Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure
  15. Spezielle Probleme beim Intensivpatienten
  16. Hepatic dysfunction contributes to coagulation disturbances in patients undergoing whole body hyperthermia by use of extracorporeal circulation
  17. Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura
  18. Treatment of thrombotic microangiopathy with a focus on new treatment options
  19. Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry
  20. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry
  21. Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma
  22. Difficult clinical challenges in haemophilia: international experiential perspectives
  23. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease
  24. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry
  25. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)
  26. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)
  27. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura
  28. Primäre Immunthrombozytopenie des Erwachsenen – Diagnostik und Therapie, Konsensus-Statement der Österreichischen Gesellschaft für Hämatologie und Onkologie (ÖGHO)
  29. Inverse correlation of free and immune complex-sequestered anti-ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura
  30. Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial
  31. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura
  32. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies
  33. Postoperative paraneoplastic factor VIII auto-antibodies in patients with solid tumours
  34. Whole body hyperthermia by extracorporeal circulation in spontaneously breathing sarcoma patients: Hemodynamics and oxygen metabolism
  35. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura
  36. The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients
  37. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease
  38. Blood coagulation disorders in septic patients
  39. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo
  40. Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML
  41. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura
  42. Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age
  43. The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera
  44. Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland
  45. Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications
  46. PCR-monitoring of minimal residual leukaemia after conventional chemotherapy and bone marrow transplantation in BCR-ABL-positive acute lymphoblastic leukaemia
  47. Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: A prospective randomized pilot trial
  48. Plasma levels of P-selectin are determined by platelet turn-over and the P-selectin Thr715Pro polymorphism
  49. Human protein C concentrates for replacement therapy in congenital and acquired protein C deficiency
  50. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy
  51. Is there an association between hemostatic abnormalities and the outcome of acute lung injury?*
  52. THE EFFECT OF PROTEIN C REPLACEMENT ON COAGULOPATHY IN ADULTS WITH INFECTIOUS PURPURA FULMINANS.
  53. Unraveling the immunologic response in thrombotic thrombocytopenic purpura
  54. Treatment of adult patients with sepsis-induced coagulopathy and purpura fulminans using a plasma-derived protein C concentrate (CeprotinR)
  55. Antiplatelet therapy prior to carotid endarterectomy – still room for improvement
  56. The effects of supra-normal protein C levels on markers of coagulation, fibrinolysis and inflammation in a human model of endotoxemia
  57. Respiratory failure after stem cell transplantation: Improved outcome with non-invasive ventilation
  58. Brief Report: Practicability and safety of amphotericin B deoxycholate as continuous infusion in neutropenic patients with hematological malignancies
  59. High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience
  60. On the Evaluation of the ISTH Score for Overt Disseminated Intravascular Coagulation
  61. Antithrombotic Strategies in Vascular Surgery: Evidence and Practice
  62. Predicting the course of sepsis: The next step?*
  63. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation
  64. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis
  65. Stability of coagulation factors in thawed, solvent/detergent-treated plasma during storage at 4 oC for 6 days
  66. Fibrin sealant produced by the CryoSealR FS System: product chemistry, material properties and possible preparation in the autologous preoperative setting
  67. Evaluation of an end-tidal portable ETCO2 colorimetric breath indicator (COLIBRI)
  68. Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse
  69. Myocardial involvement in a patient with Burkitt's lymphoma mimicking hypertrophic cardiomyopathy
  70. Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb® immunoadsorption
  71. Is the determination of anti-beta2 glycoprotein I antibodies useful in patients with venous thromboembolism without the antiphospholipid syndrome?
  72. Efficacy and tolerability of non-invasive ventilation delivered via a newly developed helmet in immunosuppressed patients with acute respiratory failure
  73. Treatment concepts for elderly patients with acute myeloid leukemia
  74. Pathophysiologie und Therapie von Sepsis-assoziierten Gerinnungsstorungen
  75. Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry
  76. Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions
  77. Treatment of acquired factor viii autoantibodies by immunoadsorption
  78. Impact of the factor II: G20210A variant on the risk of venous thromboembolism in relatives from families with the factor V: R506Q mutation
  79. Platelet-reactive HLA antibodies associated with low posttransfusion platelet increments:a comparison between the monoclonal antibody-specific immobilization of platelet antigens assay and the lymphocytotoxicity test
  80. Prospective Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia with Inversion(16) by CBFβ/MYH11 RT-PCR: Implications for a Monitoring Schedule and for Treatment Decisions
  81. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb)
  82. Prognosis of patients with a second relapse of acute myeloid leukemia
  83. Local anticoagulation of the extracorporeal circuit with heparin and subsequent neutralization with protamine during immunoadsorption
  84. Prostaglandin E1 does not influence plasmatic coagulation, hepatic synthesis, or postoperative blood loss in patients after coronary-artery bypass grafting
  85. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems
  86. The ?typical? immunophenotype of acute promyelocytic leukemia (APL-M3): Does it prove true for the M3-variant?
  87. The “typical” immunophenotype of acute promyelocytic leukemia (APL‐M3): Does it prove true for the M3‐variant?
  88. Prolonged Third Remission in a Patient With Acute Promyelocytic Leukemia After Consolidation Chemotherapy With Intermittent Intermediate Dose Ara-C and Maintenance With Intermittent all-transRetinoic Acid (ATRA)
  89. Die Immunadsorption zur Behandlung von Gerinnungsinhibitoren: Ergebnisse der Wiener Gruppe
  90. Immunologic recovery of patients given CD34-selected peripheral blood progenitor cell transplantation for malignant diseases
  91. Homocysteine levels in polycythaemia vera and essential thrombocythaemia
  92. Homocysteine levels in polycythaemia vera and essential thrombocythaemia
  93. Post-transplant acute myeloid leukemia (PT-AML)
  94. Extracorporeal Immunoadsorption for the Treatment of Haemophilic Patients with Inhibitors to Factor VIII or IX
  95. Hypofibrinogenemia in non-M3 acute myeloid leukemia. Incidence, clinical and laboratory characteristics and prognosis
  96. Recombinant human megakaryocyte growth and development factor increases levels of circulating haemopoietic progenitor cells post chemotherapy in patients with acute myeloid leukaemia
  97. 2 Acquired factor V inhibitors
  98. Leukemia-free survival and mortality in patients with refractory or relapsed acute leukemia given marrow transplants from sibling and unrelated donors
  99. Elimination von erworbenen Gerinnungsinhibitoren mit extrakorporaler Immunadsorption (Ig-Therasorb)
  100. Therapie der thrombotisch-thrombozytopenischen Purpura (TTP) bei kritisch kranken Patienten
  101. 80 Phenotypic analysis of endosteal cells in myelodysplastic syndromes and other hemopoietic disorders
  102. Prostaglandin E sub 1 Inhibits Platelet Decrease after Massive Blood Transfusions during Major Surgery
  103. Specificities of anti-platelet antibodies in multitransfused patients with haemato-oncological disorders
  104. ORAL CONTRACEPTIVES ENHANCE THE RISK OF CLINICAL MANIFESTATION OF VENOUS THROMBOSIS AT A YOUNG AGE IN FEMALES HOMOZYGOUS FOR FACTOR V LEIDEN
  105. MICROANGIOPATHY FOLLOWING ALLOGENEIC MARROW TRANSPLANTATION ASSOCIATION WITH CYCLOSPORINE AND METHYLPREDNISOLONE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS
  106. MICROANGIOPATHY FOLLOWING ALLOGENEIC MARROW TRANSPLANTATION ASSOCIATION WITH CYCLOSPORINE AND METHYLPREDNISOLONE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS
  107. Rapid elimination of a high-titer spontaneous factor V antibody by extracorporeal antibody-based immunoadsorption and immunosuppression
  108. Kinetics of minimal residual disease during induction/consolidation therapy in standard-risk adult B-lineage acute lymphoblastic leukemia
  109. Enhanced serum levels of thiobarbituric-acid-reactive substances in diabetes mellitus
  110. Dexverapamil as resistance modifier in acute myeloid leukaemia
  111. High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) — a single-institution study
  112. PML-RARα PCR positivity in the bone marrow of patients with APL precedes haematological relapse by 2–3 months
  113. Ventilation With the Combitube During Tracheotomy
  114. Apolipoprotein (a) Levels and Atherogenic Lipid Fractions in Relation to the Degree of Urinary Albumin Excretion in Type 2 Diabetes mellitus
  115. R-metHuG-CSF Combined with Chemotherapy for Treatment of Adult ALL — Pilot Study
  116. Thrombogenic factors are related to urinary albumin excretion rate in Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetic patients
  117. Effectivity of Combituben™ in patient with cardiac arrest
  118. 079 Lipid peroxidation products in diabetics
  119. Diagnostic Value of Hemostatic Parameters for Prediction of Complications in Patients Undergoing Aorto-Coronary Bypass Grafting
  120. The effect of near-normoglycaemic control on plasma levels of coagulation factor VII and the anticoagulant proteins C and S in insulin-dependent diabetic patients
  121. Replacement therapy for a homozygous protein C deficiency-state using a concentrate of human protein C and S
  122. Quantitative determination of human protein C evaluation of a “fast” functional assay in comparison to a “traditional” functional and an immunological assay
  123. Whole blood aggregometry and platelet adenine nucleotides during cardiac surgery
  124. Plasma levels of protein C and protein S in patients with vasculopathy
  125. Treatment of Adults with Sepsis-Induced Coagulopathy and Purpura Fulminans with a Plasma-Derived Protein C Concentrate (Ceprotin)